Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia

Bichoy Gabra, Oncology Infusion Pharmacy Services Manager at Moffitt Cancer Center, shared on X:

“Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination chemotherapy. The addition of blinatumomab, a bispecific T-cell engager (BiTE) molecule that is approved for the treatment of relapsed, refractory, and MRD-positive BCP-ALL, has significantly improved overall survival in MDR-negative BCP-ALL.”

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

Authors: Mark R. Litzow, Zhuoxin Sun, Ryan J. Mattison, Elisabeth M. Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Matthew J. Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner, Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A. Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali R. Bhave, Elad Sharon, Richard F. Little, Harry P. Erba, Richard M. Stone, Selina M. Luger, Charles G. Mullighan and Martin S. Tallman.

BiTEs Overview.

List of Approved BiTE Antibodies in Hematology/Oncology.

Source: Bichoy Gabra/X